Autopsy report · NCT01591512

A Prospective Longitudinal Collection of Subjects Diagnosed With Small Cell Lung Cancer

“Decision was made by Sponsor to stop the trial.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year after it had already started.
• Ran for about 1 year 2 months before it stopped.
• 4 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Sponsor

Fujirebio Diagnostics, Inc.

Sponsor type

Industry

Conditions

Small Cell Lung Cancer

Participants

4

Sites

4

Countries

United States

Trials that died the same way

• CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)
  “Sponsor decision to not initiate the trial” (84% match in meaning)
• Phase IIb Clinical Trial of Recombinant Novel Coronavirus Pneumonia (COVID-19) Vaccine (Sf9 Cells)
  “Sponsor decided to cancel this trial.” (84% match in meaning)
• A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients
  “Trial was cancelled by Sponsor” (83% match in meaning)
• A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
  “Sponsor decision not to start trial” (80% match in meaning)
• Pancreatic Enzyme Supplementation for Celiac Disease
  “The trial was terminated prematurely by the sponsor for administrative reasons.” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.